Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1996-12-17
|
| pubmed:abstractText |
Thirty-three patients with muscle-infiltrating T2-T3a bladder carcinoma were treated by TUR through the full thickness of the bladder wall and extended into the perivesical fat. The solitary tumours were not more than 4 cm in diameter. Histology proved in every case tumour stages of pT2 (17 patients) or pT3a (16 patients), G2 or G3 transitional cell carcinoma and negative mucosal biopsies. After TUR the patients received 1 or 2 cycles of chemotherapy: 60 mg of doxorubicin, 50 mg of cisplatin, 1 g of 5-fluorouracil administered into the ipsilateral hypogastric artery. There was no perioperative mortality but one patient died of complications related to chemotherapy. During the first year of follow-up relapses of muscle-invasive cancer were observed in 3 patients (10%), two were subjected to cystectomy and one to repeated TUR. With a median follow-up of 34 months 27 patients are alive and have functional bladder. The actual 3-year and 5-year survival rates were 17/21 (81%) and 6/9 (67%), respectively. The results of this study suggest that in strictly selected patients extended TUR and intra-arterial chemotherapy may be a bladder-preserving treatment modality for muscle-invasive bladder cancer. Regular (three monthly cystoscopy, cytology, biopsy, CT) investigations and follow-up are necessary to detect recurrences.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0301-1623
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
181-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8836786-Aged,
pubmed-meshheading:8836786-Aged, 80 and over,
pubmed-meshheading:8836786-Antibiotics, Antineoplastic,
pubmed-meshheading:8836786-Antimetabolites, Antineoplastic,
pubmed-meshheading:8836786-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8836786-Carcinoma, Transitional Cell,
pubmed-meshheading:8836786-Cisplatin,
pubmed-meshheading:8836786-Combined Modality Therapy,
pubmed-meshheading:8836786-Cystectomy,
pubmed-meshheading:8836786-Doxorubicin,
pubmed-meshheading:8836786-Female,
pubmed-meshheading:8836786-Fluorouracil,
pubmed-meshheading:8836786-Follow-Up Studies,
pubmed-meshheading:8836786-Humans,
pubmed-meshheading:8836786-Injections, Intra-Arterial,
pubmed-meshheading:8836786-Male,
pubmed-meshheading:8836786-Middle Aged,
pubmed-meshheading:8836786-Survival Rate,
pubmed-meshheading:8836786-Urinary Bladder Neoplasms
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Transurethral resection and intra-arterial chemotherapy for muscle-invasive bladder cancer.
|
| pubmed:affiliation |
Department of Urological Surgery, Municipal Péterfy Sándor Street Hospital, Budapest, Hungary.
|
| pubmed:publicationType |
Journal Article
|